



BSW Formulary Updates and Recent Decisions – September 2025

New additions to BSWformulary and Change in Traffic Light Status (TLS)

- **Nalvee** – dydrogesterone-only treatment for HRT added as an option for non-hysterectomised women receiving oestrogen therapy with **GREEN** traffic light for all indications.
- **Enoxaparin (Inhixa)** – added for RUH only as a cost-effective LMWH alternative to dalteparin. Traffic light is dependent on indication, see formulary entry for further information, SCAs & guidelines. GWH and SFT will also be switching to this LMWH in a few months' time.
- **Dienogest** – change of traffic light to **AMBER** for the treatment of endometriosis.

New and Updated Prescribing Guidelines and Shared Care Agreements

- **Generic Dapagliflozin is now first line for all indications and Semaglutide first line in T2DM for all NEW patients**– associated prescribing guidance have been updated to reflect cost effective prescribing, please see individual [Prescribing Guidance](#) on BSW website for further information.
- **Testosterone for Men Prescribing Guidance** – new prescribing guidance providing prescribers with relevant information and monitoring advice. This is within the BSW primary care LCS for payment of monitoring.
- **Topiramate PPP** – new pregnancy prevention programme for topiramate which includes searches to enable primary care to identify patients and a pathway for each indication.
- **ONS Prescribing Statement** – resource which provides information on the prescribing of ONS after discharge from hospital.

Minor amendments to Netformulary

- Discontinuation information added to relevant entries. The Levemir working group are ensuring safe switching for these patients.
- Dapagliflozin brand has been replaced with the generic on formulary and guidelines have been updated.
- New licensed hydrocortisone liquid added for paediatric patients and unlicensed formulation removed.
- the cost of COVID treatments has increased so not all pharmacies will stock them, there is a list of the 6 pharmacies that will hold stock and others can order and obtain within 24 hours.

What the BSW ICB formulary team are currently working on

- HRT guidance update
- Insulin formulary update
- Changing Denosumab SCA to guidance
- Producing Amiodarone guidance
- Dienogest guidance

The BSW joint formulary remains under construction and is designed to be an evolving, dynamic resource. We are working to ensure the messages on GP prescribing systems and Optimise Profiles are in line with the joint formulary. If you discover information you believe to be inaccurate or misleading, or for further information, email bswicb.formulary@nhs.net